OS Therapies Inc. (OSTX) completed a $5.25 million registered direct offering of common stock and warrants on April 2, 2026, pricing the shares at $1.40 each. The transaction included pre‑funded warrants and one additional warrant per share, providing the company with a new source of equity capital.
The company also expects to receive approximately $4 million in non‑dilutive funds from VAT refunds and R&D tax credits through its U.K. subsidiary, with roughly $2 million anticipated in Q2 2026 and another $2 million in H2 2026. Combined, the proceeds will extend OS Therapies’ cash runway beyond the previously limited two‑month horizon into 2027, giving the company time to support operations and advance its lead candidate, OST‑HER2, toward regulatory milestones in the U.S., U.K., and Europe.
The financing is intended to bridge a severe liquidity gap that had left the company with less than two months of runway without additional financing. By securing the equity raise and the expected non‑dilutive funds, OS Therapies can continue to fund the development and regulatory submission schedule for OST‑HER2, which includes a BLA, MAA, and CMA filing in 2026 and early market‑access authorizations that could trigger eligibility for a Priority Review Voucher under its Rare Pediatric Disease Designation.
Prior year financials highlight the urgency of the capital raise: OS Therapies reported a net loss of $28.75 million ($0.98 per share) for 2025, compared with a $8.88 million loss ($1.28 per share) in 2024. The widening loss underscores the company’s ongoing liquidity challenges and the importance of the new capital infusion.
Management emphasized that the capital raise, combined with the expected non‑dilutive funding, will support operations as the company advances toward its 2026 regulatory milestones. "This capital raise, together with the non‑dilutive funding we expect to receive from our U.K. subsidiary, is expected to support our operations as we advance toward crucial anticipated 2026 regulatory milestones for OST‑HER2 in the U.S., U.K. and Europe, including early market access authorizations and potential eligibility for a Priority Review Voucher under our Rare Pediatric Disease Designation (RPDD)."
The financing event directly addresses the liquidity crisis that had left OS Therapies with less than two months of runway, and the new capital, coupled with the anticipated non‑dilutive funds, is projected to extend the runway into 2027, providing the company with the necessary financial cushion to complete the scheduled regulatory submissions and maintain progress on its single‑asset pipeline.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.